Showing 2,371 news articles about HIV treatment

Filters Content type: Editors' picks Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

Pharmaceutical industry

Long-suffering CytoDyn withdraws HIV approval application for leronlimab, blaming clinical research organization

Editor's pick
FierceBiotech
1 November 2022
Adherence

Do questionnaires, pill counts, or gadgets tell health staff if people with HIV are taking their drugs?

Editor's pick
Liverpool School of Tropical Medicine
31 October 2022
Ageing & HIV

Metabolic complications of newer HIV drugs in older people

Editor's pick
i-Base
31 October 2022
Antibody-based treatment

GSK's ViiV gives early look at HIV broadly neutralizing antibody's power, eyes long-acting combo trial

Editor's pick
FierceBiotech
28 October 2022
Starting treatment

Long-Term Results Confirm Benefits of Early HIV Treatment

Editor's pick
POZ
26 October 2022
Antibody-based treatment

ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV

Editor's pick
ViiV press release
26 October 2022
People with limited treatment options

Lenacapavir: 75% Sub-50 Response at 52 Weeks Despite Heavy ART Experience

Editor's pick
NATAP
26 October 2022
The search for a cure

Danish-led study takes major step in pursuit of HIV cure

Editor's pick
EurekAlert
18 October 2022
Treatment for women

Standard Integrase Regimens Have Minimal Glucose Impact in Older Black Women

Editor's pick
NATAP
14 October 2022
Ageing & HIV

Biktarvy Could Be Long-Term Option for Older Adults With HIV

Editor's pick
Infectious Disease Special Edition
6 October 2022
PrEP science

For Patients Taking PrEP, Poor Adherence Drives HIV Seroconversions

Editor's pick
Physician's Weekly
5 October 2022
People with limited treatment options

FDA Approves Trogarzo for 30-Second IV Push, Simplifying HIV Treatment for Heavily Treatment-Experienced People

Editor's pick
Infectious Disease Special Edition
5 October 2022
Drug interactions & pharmacokinetics

Low levels of RPV-LA might explain failure with injectable ART despite perfect adherence

Editor's pick
i-Base
3 October 2022
New & experimental HIV treatments

5 FDA decisions to watch in the fourth quarter

Editor's pick
BioPharma Dive
3 October 2022
Bad science & bogus treatments

Treatment Action Campaign slams Thabo Mbeki over his views on HIV

Editor's pick
GroundUp
30 September 2022
Pharmaceutical industry

Under new leadership, CytoDyn ditches COVID-19 programs

Editor's pick
FierceBiotech
30 September 2022
Injectable & long-acting HIV treatment

Compassionate Use of Long-Acting Cabotegravir Plus Rilpivirine in HIV

Editor's pick
Infectious Disease Advisor
26 September 2022
New & experimental HIV treatments

Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection

Editor's pick
Merck press release
20 September 2022
Changing treatment

A Switch to B/F/TAF Keeps HIV Suppressed, Even With Mutation

Editor's pick
Medscape (requires free registration)
20 September 2022
Harm reduction

Can Substance Use Treatment Improve HIV Care?

Editor's pick
POZ
15 September 2022
Side effects

Go Slow Before Switching HIV Meds Due to Metabolic Effects

Editor's pick
Infectious Disease Special Edition
14 September 2022
Changing treatment

Inflammatory Biomarkers in HIV Support Safety of Switching to 2-Drug Antiretroviral Therapy

Editor's pick
Infectious Disease Advisor
8 September 2022
Resistance

HIV patients in Botswana get adequate treatment but not all of them – one group is slipping through the cracks

Editor's pick
The Conversation
6 September 2022
Pregnancy and vertical transmission

Dolutegravir-based antiretroviral therapies for HIV-1 effective in pregnancy

Editor's pick
EurekAlert
1 September 2022